Drug intelligence / Profile preview

Colifagina

Development stage: Unknown
Lead developer: Sant’Orsola-Malpighi University Hospital
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

Colifagina is an oral enterovaccine consisting of a polybacterial lysate of eight lysed bacterial strains. Classified as a biologic immunostimulant, it acts by stimulating IgA-mediated mucosal immune defenses within the gastrointestinal tract. It has been investigated for various gastrointestinal conditions, including acute gastroenteritis in children, functional bloating, and recurrent diverticulitis. In clinical studies, it has been evaluated as an adjunct to standard rehydration therapy to reduce the duration and severity of diarrheal episodes, particularly those associated with viral pathogens like astrovirus, rotavirus, and adenovirus.

Brand names: Colifagina
Other names: polybacterial lysateoral enterovaccine

Targets

IgA (Immunoglobulin A)

Beyond the preview

Go deeper on Colifagina.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Colifagina.

Explore the full profile